Jonathan D Grinstein

Arc Institute researchers have discovered an RNA-guided system that enables modular and programmable DNA insertions, excisions, and inversions.

Arc Institute researchers have discovered an RNA-guided system that enables modular and programmable DNA insertions, excisions, and inversions.

Single Technologies has developed a confocal-based optical system to sequence a 3D matrix for hugely parallel reactions in three dimensions.

SalioGen’s lipid nanoparticle delivery of bioengineered mammalian transposases can integrate large genes at precise genomic locations.

Moonwalk will show their first data for their two major platform components: the EpiRead and EpiWrite technologies.

Combining gentle editing and targeted delivery allows gene therapy developers to say “open sesame” to otherwise impassable obstacles.

The AI approach—the iterative processing of masses of experimental and synthetic data—blurs the distinction between computation and biology.

The co-founder and CEO of Verve Therapeutics explains his strategies for the company’s security in the face of a paused clinical trial.

The funding will enable Diagonal Therapeutics’ lead asset, discovered with its DIAGONAL platform, to undergo clinical proof of concept.

Touching Bse Episode 15: From the expansion of Nvidia’s generative artificial intelligence (AI) platform for drug discovery to AI notetakers that coach doctors to be more human, the GEN editors discuss the latest news in AI from two conferences in California: Nvidia GTC (San Jose) and Precision Med TRI-CON (San Diego).

Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.

By combining technologies, the companies will develop universal, off-the-shelf in vivo CAR T cell therapies.

AAV-based gene replacement therapy may help people with arrhythmogenic right ventricular cardiomyopathy (ARVC).

COUR Pharmaceuticals secured approximately $105 million to develop therapies to treat patients with autoimmune and inflammatory diseases.

Episode 6 (January 26, 2024): 11-year-old regains hearing after gene therapy; Kyverna uses blood draw instead of apheresis for CAR T manufacturing; DNA production technology with GSK and Elegen, StockWatch with Nvidia and Recursion; an interview with renowned cardiologist, Eric Topol, MD.

The agreement enables GSK to use Elegen’s proprietary cell-free DNA manufacturing technology to develop vaccines and medicines.

The $75 million deal will advance SandboxAQ’s computational chemistry and simulation capabilities in drug discovery and development.

Veracyte’s first application of C2i Genomics’ technology will be a muscle-invasive bladder cancer minimal residual disease (MRD) test.

Amgen has exercised its rights under an existing collaboration agreement with Generate:Biomedicines to opt in for a sixth program. This represents the first expansion of the original agreement. Amgen will make an undisclosed upfront payment and will pay up to $370 million in future milestones and royalties up to double digits for this new program.

Apertura has unveiled their engineered adeno-associated virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1), which mediates crossing of the blood-brain barrier (BBB) to enable gene therapy delivery throughout the CNS.